Outcome in 43 children presenting with metastatic Ewing sarcoma: The St. Jude Children's Research Hospital experience, 1962 to 1992

Claudio Sandoval, William H. Meyer, David M. Parham, Larry E. Kun, H. Omar Hustu, Xiaolong Luo, Charles B. Pratt

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The purpose of this work was to review the St. Jude Children's Research Hospital experience of patients presenting with metastatic Ewing sarcoma over a 30-year period. Forty-three of 212 cases of Ewing sarcoma presented with metastases at diagnosis. These patients were analyzed to determine whether primary tumor site or size, metastatic site(s), or advances in therapy have had a positive impact on survival. The overall survival for our 43 patients was 35% (95% confidence intervals, 20% to 50%). Comparing patients treated prior to 1979 with those treated after 1979, the overall survival was significantly different (P = 0.0002). Comparing overall survival between pelvic and nonpelvic primaries (P = 0.24), among metastatic sites (P = 0.83), and between tumors measuring >8 cm in diameter to tumors measuring <8 cm in diameter (P = 0.12), no significant differences were observed. Approximately one-third of patients presenting with metastatic Ewing sarcoma may achieve long-term survival. Children with metastatic Ewing sarcoma may benefit from clinical trials which intensify the doses of doxorubicin, and the highly effective combination of ifosfamide/etoposide.

Original languageEnglish (US)
Pages (from-to)180-185
Number of pages6
JournalMedical and Pediatric Oncology
Volume26
Issue number3
DOIs
StatePublished - Jan 1 1996

Fingerprint

Ewing's Sarcoma
Survival
Research
Neoplasms
Ifosfamide
Etoposide
Doxorubicin
Clinical Trials
Confidence Intervals
Neoplasm Metastasis

Keywords

  • chemotherapy
  • Ewing sarcoma
  • metastases
  • radiation therapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Outcome in 43 children presenting with metastatic Ewing sarcoma : The St. Jude Children's Research Hospital experience, 1962 to 1992. / Sandoval, Claudio; Meyer, William H.; Parham, David M.; Kun, Larry E.; Hustu, H. Omar; Luo, Xiaolong; Pratt, Charles B.

In: Medical and Pediatric Oncology, Vol. 26, No. 3, 01.01.1996, p. 180-185.

Research output: Contribution to journalArticle

Sandoval, Claudio ; Meyer, William H. ; Parham, David M. ; Kun, Larry E. ; Hustu, H. Omar ; Luo, Xiaolong ; Pratt, Charles B. / Outcome in 43 children presenting with metastatic Ewing sarcoma : The St. Jude Children's Research Hospital experience, 1962 to 1992. In: Medical and Pediatric Oncology. 1996 ; Vol. 26, No. 3. pp. 180-185.
@article{404b5e3fcc704d309afc9094beda1fcd,
title = "Outcome in 43 children presenting with metastatic Ewing sarcoma: The St. Jude Children's Research Hospital experience, 1962 to 1992",
abstract = "The purpose of this work was to review the St. Jude Children's Research Hospital experience of patients presenting with metastatic Ewing sarcoma over a 30-year period. Forty-three of 212 cases of Ewing sarcoma presented with metastases at diagnosis. These patients were analyzed to determine whether primary tumor site or size, metastatic site(s), or advances in therapy have had a positive impact on survival. The overall survival for our 43 patients was 35{\%} (95{\%} confidence intervals, 20{\%} to 50{\%}). Comparing patients treated prior to 1979 with those treated after 1979, the overall survival was significantly different (P = 0.0002). Comparing overall survival between pelvic and nonpelvic primaries (P = 0.24), among metastatic sites (P = 0.83), and between tumors measuring >8 cm in diameter to tumors measuring <8 cm in diameter (P = 0.12), no significant differences were observed. Approximately one-third of patients presenting with metastatic Ewing sarcoma may achieve long-term survival. Children with metastatic Ewing sarcoma may benefit from clinical trials which intensify the doses of doxorubicin, and the highly effective combination of ifosfamide/etoposide.",
keywords = "chemotherapy, Ewing sarcoma, metastases, radiation therapy",
author = "Claudio Sandoval and Meyer, {William H.} and Parham, {David M.} and Kun, {Larry E.} and Hustu, {H. Omar} and Xiaolong Luo and Pratt, {Charles B.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1002/(SICI)1096-911X(199603)26:3<180::AID-MPO6>3.0.CO;2-G",
language = "English (US)",
volume = "26",
pages = "180--185",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Outcome in 43 children presenting with metastatic Ewing sarcoma

T2 - The St. Jude Children's Research Hospital experience, 1962 to 1992

AU - Sandoval, Claudio

AU - Meyer, William H.

AU - Parham, David M.

AU - Kun, Larry E.

AU - Hustu, H. Omar

AU - Luo, Xiaolong

AU - Pratt, Charles B.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - The purpose of this work was to review the St. Jude Children's Research Hospital experience of patients presenting with metastatic Ewing sarcoma over a 30-year period. Forty-three of 212 cases of Ewing sarcoma presented with metastases at diagnosis. These patients were analyzed to determine whether primary tumor site or size, metastatic site(s), or advances in therapy have had a positive impact on survival. The overall survival for our 43 patients was 35% (95% confidence intervals, 20% to 50%). Comparing patients treated prior to 1979 with those treated after 1979, the overall survival was significantly different (P = 0.0002). Comparing overall survival between pelvic and nonpelvic primaries (P = 0.24), among metastatic sites (P = 0.83), and between tumors measuring >8 cm in diameter to tumors measuring <8 cm in diameter (P = 0.12), no significant differences were observed. Approximately one-third of patients presenting with metastatic Ewing sarcoma may achieve long-term survival. Children with metastatic Ewing sarcoma may benefit from clinical trials which intensify the doses of doxorubicin, and the highly effective combination of ifosfamide/etoposide.

AB - The purpose of this work was to review the St. Jude Children's Research Hospital experience of patients presenting with metastatic Ewing sarcoma over a 30-year period. Forty-three of 212 cases of Ewing sarcoma presented with metastases at diagnosis. These patients were analyzed to determine whether primary tumor site or size, metastatic site(s), or advances in therapy have had a positive impact on survival. The overall survival for our 43 patients was 35% (95% confidence intervals, 20% to 50%). Comparing patients treated prior to 1979 with those treated after 1979, the overall survival was significantly different (P = 0.0002). Comparing overall survival between pelvic and nonpelvic primaries (P = 0.24), among metastatic sites (P = 0.83), and between tumors measuring >8 cm in diameter to tumors measuring <8 cm in diameter (P = 0.12), no significant differences were observed. Approximately one-third of patients presenting with metastatic Ewing sarcoma may achieve long-term survival. Children with metastatic Ewing sarcoma may benefit from clinical trials which intensify the doses of doxorubicin, and the highly effective combination of ifosfamide/etoposide.

KW - chemotherapy

KW - Ewing sarcoma

KW - metastases

KW - radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0030045055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030045055&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-911X(199603)26:3<180::AID-MPO6>3.0.CO;2-G

DO - 10.1002/(SICI)1096-911X(199603)26:3<180::AID-MPO6>3.0.CO;2-G

M3 - Article

C2 - 8544800

AN - SCOPUS:0030045055

VL - 26

SP - 180

EP - 185

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -